Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01324479
Title Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Capmatinib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
University of Chicago SC Chicago Illinois 60637 United States Details
Karmanos Cancer Institute Wayne St Karmanos Detroit Michigan 48201 United States Details
Sarah Cannon Research Institute Dept of Onc Nashville Tennessee 37203 United States Details
University of Texas/MD Anderson Cancer Center Dept of Onc Houston Texas 77030-4009 United States Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Woolloongabba Queensland 4102 Australia Details
Novartis Investigative Site Ottawa Ontario K1H 8L6 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site La Tronche 38700 France Details
Novartis Investigative Site LILLE Cédex 59037 France Details
Novartis Investigative Site Strasbourg Cedex 67091 France Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Freiburg 79106 Germany Details
Novartis Investigative Site Gottingen 37075 Germany Details
Novartis Investigative Site Hannover 30625 Germany Details
Novartis Investigative Site Oldenburg 26121 Germany Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Shatin, New Territories Hong Kong Details
Novartis Investigative Site Haifa 3525408 Israel Details
Novartis Investigative Site Kfar Saba 4428164 Israel Details
Novartis Investigative Site Ramat Gan 5265601 Israel Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Ancona AN 60126 Italy Details
Novartis Investigative Site Meldola FC 47014 Italy Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20162 Italy Details
Novartis Investigative Site Reggio Emilia RE 42123 Italy Details
Novartis Investigative Site Seoul Gyeonggi Do 03080 Korea, Republic of Details
Novartis Investigative Site Gyeonggi do Korea 10408 Korea, Republic of Details
Novartis Investigative Site Seoul Korea 05505 Korea, Republic of Details
Novartis Investigative Site Seoul Korea 06351 Korea, Republic of Details
Novartis Investigative Site Seoul Seocho Gu 06591 Korea, Republic of Details
Novartis Investigative Site Utrecht The Netherlands 3508 GA Netherlands Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Rotterdam 3075 EA Netherlands Details
Novartis Investigative Site Oslo NO-0424 Norway Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Granada Andalucia 18014 Spain Details
Novartis Investigative Site Oviedo Asturias 33006 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28046 Spain Details
Novartis Investigative Site Zaragoza 50009 Spain Details
Novartis Investigative Site Tainan Taiwan ROC 70403 Taiwan Details
Novartis Investigative Site Taipei Taiwan ROC 10041 Taiwan Details
Novartis Investigative Site Songkhla Hat Yai 90110 Thailand Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field